U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07195669) titled 'RCT: Suzetrigine vs Norco for Post-op Pain' on Sept. 24.
Brief Summary: Journavx (suzetrigine) is a novel non-opioid analgesic that is FDA approved for acute pain management and may offer a promising alternative for managing postoperative pain. Suzetrigine is selective inhibitor of the sodium channel NaV1.8, for managing acute pain. NaV1.8, a sodium channel, plays a key role in transmitting pain signals. Importantly, this channel is minimally expressed in the brain, enabling effective pain control without the potential central nervous system side effects of respiratory depression and addiction associated with opioids. Clinical tria...